Showing 331-340 of 345 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| A Novel Ultra-Rapid Insulin | Wayne State University | Zhiqiang Cao | Improving Lives | 01-November-2025 to 31-October-2026 | $299,994.92 |
| Orally Delivered Glucose-Responsive Insulin | Wayne State University | Zhiqiang Cao | Improving Lives | 01-June-2024 to 31-May-2026 | $274,499.13 |
| Intrinsic Tolerance in GINS: Dissecting the HVEM/BTLA Axis Driving Hypoimmunogenicity | Weill Medical College of Cornell University | Anna Ada Dattoli | Cures | 01-April-2026 to 31-March-2027 | $199,999.32 |
| Role of oxidative post-translational modifications in generating neoepitopes | Weill Medical College of Cornell University | Laura Santambrogio | Cures | 01-April-2025 to 31-March-2028 | $600,000.00 |
| Co-transplantation of adaptive human endothelium and islets within encapsulated angiogenic hydrogels for durable engraftment | Weill Medical College of Cornell University | Shahin Rafii | Cures | 01-December-2023 to 30-November-2026 | $1,000,000.00 |
| Chemical Perturb-seq to identify small molecules controlling the maturation and survival on human beta cells | Weill Medical College of Cornell University | Xiaoshan Zhang | Cures | 01-March-2026 to 28-February-2029 | $256,285.00 |
| Localized immune modulation to enable long-term beta cell survival | William Marsh Rice University | Omid Veiseh | Cures | 01-September-2022 to 31-January-2026 | $600,000.00 |
| Spatial and temporal regulation of proangiogenic factors to support islet cell transplantation | William Marsh Rice University | Omid Veiseh | Cures | 01-January-2025 to 31-December-2027 | $900,000.00 |
| Phenotyping RElatives of persons with Diabetes with CGM and Tests of beta-cell function and health (PREDICT): an integrated longitudinal assessment of deep metabolic phenotyping and CGM metrics in youth at risk for T1D | Yale University | Alfonso Galderisi | Cures | 01-February-2023 to 30-September-2026 | $747,380.88 |
| Genetic dissection of GLP1R signaling in type 1 diabetes outcomes | Yale University | David Alagpulinsa | Improving Lives | 01-April-2026 to 31-March-2027 | $180,829.34 |